Other potential treatments for diabetic nephropathy include mineralocorticoid receptor antagonists, phosphodiesterase inhibitors (pentoxifylline), pyridoxamine, apoptosis signal-regulating kinase 1 (ASK1) inhibitors, bardoxolone methyl, and endothelin (ET) receptor antagonists [13]. This evidence concerns the gene MAP3K5 and diabetic kidney disease.